αβ-T cells

Abstract

Adoptive cell therapy using autologous αβ-T cells is one of the most effective treatments for various cancers and has minimal side effects. αβ-T cells have the ability to recognize the cancer antigens that present with human leukocyte antigen (HLA) molecules on the cancer cells and kill them by secreting several granules, such as perforin, granzyme, or granulysin. Several clinical effects have been defined in clinical trials, but standardized treatment approaches have not been established. Because of the difficulty of dealing with several regulations and the high costs, there have been very few large clinical trials. Even so, recent technical advances in such fields as genetic engineering may make it possible to cure various cancers using new candidates for αβ-T-cell therapy. It is expected that safe and effective αβ-T-cell therapy will be developed as a standard cancer therapy in the near future.